Angeles Wealth Management LLC Decreases Position in Becton, Dickinson and Company (NYSE:BDX)

Angeles Wealth Management LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,679 shares of the medical instruments supplier’s stock after selling 50 shares during the quarter. Angeles Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $405,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Van ECK Associates Corp raised its stake in shares of Becton, Dickinson and Company by 2.4% in the third quarter. Van ECK Associates Corp now owns 14,288 shares of the medical instruments supplier’s stock valued at $3,437,000 after buying an additional 339 shares during the period. Janney Montgomery Scott LLC increased its holdings in Becton, Dickinson and Company by 0.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 123,614 shares of the medical instruments supplier’s stock worth $29,804,000 after acquiring an additional 472 shares during the last quarter. Optas LLC raised its stake in Becton, Dickinson and Company by 8.9% in the 3rd quarter. Optas LLC now owns 3,205 shares of the medical instruments supplier’s stock valued at $773,000 after acquiring an additional 262 shares during the period. Argonautica Private Wealth Management Inc. lifted its holdings in Becton, Dickinson and Company by 1.8% during the third quarter. Argonautica Private Wealth Management Inc. now owns 10,740 shares of the medical instruments supplier’s stock valued at $2,589,000 after purchasing an additional 187 shares during the last quarter. Finally, First Interstate Bank boosted its position in Becton, Dickinson and Company by 18.4% during the third quarter. First Interstate Bank now owns 1,622 shares of the medical instruments supplier’s stock worth $391,000 after purchasing an additional 252 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $235.24 on Monday. The company has a 50-day simple moving average of $237.56 and a two-hundred day simple moving average of $235.09. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92. The firm has a market cap of $67.99 billion, a price-to-earnings ratio of 48.40, a PEG ratio of 1.75 and a beta of 0.43. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.96 earnings per share. On average, equities analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Analyst Upgrades and Downgrades

BDX has been the topic of several research reports. Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Raymond James dropped their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.